al risk&quot; studies, and thus may be reviewed
through an expedited review procedure [21 CFR 56.110]. FDA considers all SR studies to
present more than minimal risk, and thus, full IRB review is necessary. In making its
determination on approval, the IRB should consider the risks and benefits of the medical
device compared to the risks and benefits of alternative devices or procedures. </p>

<p><i>Also see these FDA Information Sheets:</i><br>
  <a href="#risk">&quot;Significant Risk and Nonsignific